Table 3.
Genes increased in the PC-3 D12 Docetaxel Resistant Cell line
| PC-3 D12 vs PC-3 Ag Gene Name | Accession no. | Fold change | p value |
|---|---|---|---|
| NAIP | NM_004536 | 28.14023 | NA |
| BCL2A1 | NM_001114735 | 9.956213 | 7.84E-06 |
| CLU | NM_001171138 | 6.138126 | 0.019757 |
| TNFRSF1B | NM_001066 | 4.568718 | NA |
| ATM | NM_000051 | 2.884063 | 0.013665 |
| FOXO1 | NM_002015 | 2.746056 | 0.0167 |
| MAP2K4 | NM_003010 | 2.456245 | 0.13486 |
| APAF1 | NM_001160 | 2.264102 | 0.34641 |
| NOL3 | NM_001185057 | 1.946074 | 0.101148 |
| CHEK1 | NM_001114121 | 1.554884 | 0.433367 |
| BNIP3L | NM_004331 | 1.514918 | 0.113779 |
| NBN | NM_002485 | 1.505995 | 0.051555 |
Total mRNA was extracted from the PC-3 Ag and PC-3 D12 cells and used on custom designed Low Density Arrays (LDA) which included the transcriptional profile probes for the IAPs, death receptors, death ligands, and signalling molecules as well as genes involved in cell cycle regulation, DNA damage and repair and chemotherapy resistance. Additional File 1, lists the 95 genes chosen for inclusion, and their function. Genes whose expression has increased (fold increase > 1.5) in the Docetaxel resistanct PC-3 D12 subline compared to the PC-3 Ag. n = 3.